Zymeworks Announced Saturday At ESMO, Phase 1 ZW191 Data Showing 64.5% Confirmed Objective Response Rate At 6.4 Mg/Kg Dose In Patients With High-Grade Serous Platinum-Resistant Ovarian Cancer

Loading news article.

Zymeworks Announced Saturday At ESMO, Phase 1 ZW191 Data Showing 64.5% Confirmed Objective Response Rate At 6.4 Mg/Kg Dose In Patients With High-Grade Serous Platinum-Resistant Ovarian Cancer | WAPE

Zymeworks Announced Saturday At ESMO, Phase 1 ZW191 Data Showing 64.5% Confirmed Objective Response Rate At 6.4 Mg/Kg Dose In Patients With High-Grade Serous Platinum-Resistant Ovarian Cancer

Article summary

Related companies

Comments —